https://www.selleckchem.com/pr....oducts/vevorisertib-
Current chemotherapy regimens for cholangiocarcinoma (CCA) yield poor outcomes, with a median overall survival of 12 months. Recent data on the genomic landscape of CCAs have created opportunities for targeted therapy. Yet, data regarding its efficacy are scarce. We aimed to describe the genomic landscape of a CCA patient cohort using next-generation sequencing (NGS), focusing on the ERBB/EFGR pathway and assessing response to anti-HER2 agents. Tissue samples of intrahepatic CCA (IHCC) and extrahepatic CCA (EHC
Like
Comment
Share
